HALLE/SAALE, Germany, 05 May 2015 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, today announced that Ulrich Heiser, PhD, Director Medicinal Chemistry/CMC at Probiodrug AG has been invited to present at the GTC 9th Drug Design & Medicinal Chemistry Conference, taking place from May 5-6, 2015 in Berlin, Germany.

The presentation entitled, "Glutaminyl Cyclase Inhibition: A New Approach for the Treatment of AD" is scheduled within Session 2 "Emerging Targets for Therapeutic Intervention" on Tuesday, May 5th 2015 from 11.50 am to 12.40 pm.

The presentation will introduce the key concept of Probiodrug's new approach for AD treatment, as well as information on the identification of the lead compound PQ912. The presentation addresses the medicinal chemistry strategy as well as pre-clinical in vitro and in vivo efficacy data. Furthermore, results from the successfully completed Phase I clinical trial for PQ912 will be presented.

For more information please visit https://www.gtcbio.com/conferences/drug-design-medicinal-chemistry-agenda.

For more information please contact:
Dr Konrad Glund, CEO, Probiodrug
Email: contact@probiodrug.de

Hume Brophy
Email: probiodrug@humebrophy.com
Tel: +44 (203) 440 5653